CureDuchenne
Debra Miller is the CEO and founder of CureDuchenne. Debra founded the organization in 2003 and has made significant contributions to accelerating drug development towards a cure for Duchenne. Debra also established CureDuchenne Ventures, LLC in 2014, and received FDA approval for Exondys51 in 2016. Debra has been recognized with awards for their work, including the 2020 Nonprofit of the Year award. In addition, Debra launched CureDuchenne Link in 2021 to connect information from the Duchenne and Becker community directly to researchers. Prior to CureDuchenne, Debra worked as a Regional Manager at PC Magazine. Debra holds a BA in Communications Studies from UCLA.
CureDuchenne
CureDuchenne is the global leader in Duchenne research, patient care and innovation. We are committed to improving the lives of those affected by Duchenne through accelerating research, improving care and empowering the community. cureduchenne.org Founded by Paul and Debra Miller in 2003, after their son was diagnosed with the disease, CureDuchenne combines fundraising and venture philanthropy leveraging donor dollars to maximize support for promising research into effective treatments for those suffering from Duchenne. With transparency as a core value, investment proceeds are redeployed to support research and other mission critical programs to find a cure.